TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $49.00 Consensus Target Price from Brokerages

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $49.00.

Several research firms recently weighed in on TGTX. HC Wainwright assumed coverage on shares of TG Therapeutics in a research note on Monday, October 6th. They set a “buy” rating and a $60.00 price objective on the stock. The Goldman Sachs Group raised shares of TG Therapeutics to a “hold” rating and set a $37.00 price objective on the stock in a research report on Thursday, July 10th. B. Riley boosted their target price on shares of TG Therapeutics from $53.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of TG Therapeutics in a report on Wednesday, October 8th.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the sale, the director directly owned 94,061 shares in the company, valued at $3,032,526.64. This represents a 18.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 10.64% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Ameritas Advisory Services LLC acquired a new stake in TG Therapeutics during the 2nd quarter valued at approximately $25,000. Johnson Financial Group Inc. bought a new position in TG Therapeutics during the 2nd quarter valued at $25,000. NBC Securities Inc. raised its stake in shares of TG Therapeutics by 82,300.0% during the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 823 shares during the period. Golden State Wealth Management LLC raised its stake in TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 433 shares during the period. Finally, SVB Wealth LLC bought a new stake in TG Therapeutics in the 1st quarter valued at about $37,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Down 0.2%

TGTX opened at $34.14 on Friday. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96. The company has a market capitalization of $5.42 billion, a PE ratio of 92.27 and a beta of 1.97. TG Therapeutics has a fifty-two week low of $22.61 and a fifty-two week high of $46.48. The business has a 50-day moving average of $31.74 and a 200-day moving average of $35.13.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.15). The firm had revenue of $141.15 million for the quarter, compared to the consensus estimate of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.TG Therapeutics’s quarterly revenue was up 92.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts forecast that TG Therapeutics will post 0.08 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.